PaxMedica, a clinical stage biopharmaceutical company, has announced positive top line results from the PAX-101 Phase 3 African Sleeping Sickness study. The study successfully achieved its primary endpoint and demonstrated statistically significant and clinically meaningful results. These findings are an important step towards filing an NDA for the use of PAX-101 in the treatment of African Slee..
Kintara Therapeutics, a biopharmaceutical company specializing in the development of treatments for solid tumor cancers, will be participating in the fifth annual Glioblastoma Awareness Day in Washington, D.C. This event aims to raise awareness and support for research advancements in glioblastoma (GBM). Kintara's leading treatment candidate for GBM, VAL-083, is currently being evaluated in the ..
ize innovative therapies for patients with cardiorenal diseases. Tenapanor is one such therapy, and its acceptance by China's Center for Drug Evaluation is a significant achievement for Ardelyx. With the NDA submission expected to be approved by the end of 2024, this marks a major milestone in bringing tenapanor to patients in China. Ardelyx CEO expresses gratitude towards collaboration partner ..
Clearside Biomedical's Asia-Pacific partner, Arctic Vision, has announced that its new drug application for the suprachoroidal use of Arcatus® in treating Uveitic Macular Edema has been accepted in Australia. This exciting development comes as Clearside Biomedical, Inc., a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS®..
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment   Aquestive Therapeutics, a pharmaceutical company specializing in advancing medicines to improve patients' lives, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for their product Libervant™ (diazepam) Buccal Film. The NDA is specifically for the..
